Catalyst Biosciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 64.21. In total, the insiders bought 318 090 847 and sold 5 392 312 414 CBIO shares in the last 100 trades.

Insider Power

(Last 100 transactions)
64.21
Buy 318 090 847 Shares
Sell 5 392 312 Shares

Historical Insider Trades

Date Type Action Person Amount
Nov 20, 2023 Stock Option (Right to Buy) Buy Luo Ying 3 350 897
Nov 20, 2023 Stock Option (Right to Buy) Buy Luo Ying 2 262 755
Nov 20, 2023 Stock Option (Right to Buy) Buy Ye Weiguo 1 665 115
Nov 20, 2023 Stock Option (Right to Buy) Buy Ma Songjiang 4 510 047
Nov 20, 2023 Stock Option (Right to Buy) Buy Chen Ruoyu 578 540
Nov 20, 2023 Stock Option (Right to Buy) Buy Wu Charles C 170 417
Oct 31, 2023 Stock Option (Right to Buy) Buy Luo Ying 1 866
Oct 31, 2023 Stock Option (Right to Buy) Buy Eastling Thomas Wilson 314 652
Oct 31, 2023 Stock Option (Right to Buy) Buy Eastling Thomas Wilson 1 866
Oct 31, 2023 Stock Option (Right to Buy) Buy Parry Renate 1 866
Oct 31, 2023 Stock Option (Right to Buy) Buy Chen Ruoyu 34 380
Oct 31, 2023 Stock Option (Right to Buy) Buy Usman Nassim 341 652
Oct 31, 2023 Stock Option (Right to Buy) Buy Usman Nassim 1 866
Oct 31, 2023 Stock Option (Right to Buy) Buy Ying Han 1 866
Oct 31, 2023 Stock Option (Right to Buy) Buy Carmichael Gordon 1 866
Oct 30, 2023 Common Stock Buy Luo Ying 2 840 376
Oct 30, 2023 Common Stock Buy Gni Group Ltd. 63 588 119
Oct 30, 2023 Common Stock Buy Ma Songjiang 0
Oct 30, 2023 Buy Ma Songjiang 0
Oct 30, 2023 Buy Parry Renate 0
Oct 30, 2023 Buy Ying Han 0
Oct 30, 2023 Buy Carmichael Gordon 0
Oct 30, 2023 Buy Ye Weiguo 0
Oct 30, 2023 Buy Chen Ruoyu 0
Oct 30, 2023 Buy Wu Charles C 0
Click to get the best stock tips daily for free!

About Catalyst Biosciences

Catalyst Biosciences Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD);... CBIO Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT